Medtronic saw 6.6% year over year growth in the second quarter of fiscal year 2026, according to financial results posted Nov. 18.
Five things to know:
1. Medtronic saw $9 billion in global revenue, and $4.5 billion in U.S. sales.
2. Neuroscience sales were $2.5 billion, a 4.5% increase year over year.
3. Cranial and spinal technologies saw 5.2% year over year growth with $1.3 billion. Specialty therapies and neuromodulation saw year-over-year growth of 0.9% and 8.3%, respectively.
4. Medical Surgical business was $2.2 billion, a 2.1% increase year over year, and cardiovascular sales were $3.6 billion, a 10.8% jump. Diabetes revenue was $757 million, a 10.3& year over year increase.
5. Medtronic raised its fiscal year 2026 guidance and expects 5.5% full-year growth.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
